<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131337</url>
  </required_header>
  <id_info>
    <org_study_id>EFFICAS II Version B</org_study_id>
    <nct_id>NCT02131337</nct_id>
  </id_info>
  <brief_title>TactiCathÂ® Prospective Effectiveness Pilot Study</brief_title>
  <acronym>EFFICAS II</acronym>
  <official_title>Efficacy Study on Atrial Fibrillation Percutaneous Catheter Ablation With Contact Force Support 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endosense</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EFFICAS II proposes to test the hypothesis that treatment efficacy correlates to contact&#xD;
      force parameters applied for pulmonary vein isolation (PVI) during AF ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EFFICAS II is a single-arm, prospective study, where the operator will have access to contact&#xD;
      force information and use it actively to optimize the ablation result and adapting power if&#xD;
      necessary. The endpoint will correlate contact force parameters initially applied in PV and 3&#xD;
      months PV isolation status, and compare results to those of EFFICAS I.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of pulmonary vein isolation (PVI) gaps per vein</measure>
    <time_frame>3 months</time_frame>
    <description>Number of gaps in EFFICAS 2 is lower than in EFFICAS 1 and Contact force in EFFICAS 2 has reduced variability than in EFFICAS 1. Confounding parameters such as lesion continuity will be determined for the remaining gaps in EFFICAS 2.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Contact force lesions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrophysiology study</intervention_name>
    <description>after 3 months to check for pulmonary vein isolation (PVI) status</description>
    <arm_group_label>Contact force lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is at least 18 years of age but not over 75 years of age&#xD;
&#xD;
          -  Patient has at least one episode of sustained (&gt;30s) paroxysmal atrial fibrillation&#xD;
             documented by 12-lead ECG, holter monitor, transtelephonic event monitor, telemetry&#xD;
             strip, or Pacemaker respectively implantable cardioverter defibrillator (ICD) within&#xD;
             12 months prior to enrolment&#xD;
&#xD;
          -  Patient has symptomatic paroxysmal atrial fibrillation (PAF) refractory or intolerant&#xD;
             to at least one Class I-IV anti-arrhythmic drug&#xD;
&#xD;
          -  Patient is willing and capable of complying with the study protocol requirements,&#xD;
             including the specified follow-up scheme&#xD;
&#xD;
          -  Patient provides written informed consent prior to enrolment in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not adhering to inclusion criteria&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Recent (within 3 months) cardiac events including myocardial infarction, acute&#xD;
             coronary syndrome, percutaneous coronary intervention (PCI), or valve or coronary&#xD;
             bypass grafting surgery&#xD;
&#xD;
          -  Reversible causes of Arrhythmia including thyroid disorders, acute alcohol&#xD;
             intoxication, recent (less than 3 months) major surgical procedures&#xD;
&#xD;
          -  Patient has a left atrial diameter &gt; 5.0 cm&#xD;
&#xD;
          -  Patient has persistent or long-standing persistent atrial fibrillation (AF)&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 35%&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III or IV&#xD;
&#xD;
          -  Previous left atrial heart ablation procedure, either surgical or catheter ablation&#xD;
&#xD;
          -  Patient has an intracardiac mural thrombus or has had a ventriculotomy or atriotomy&#xD;
&#xD;
          -  Patient has moderate or severe structural heart disease as demonstrated by&#xD;
             transthoracic or trans-esophageal echocardiogram of all four chambers of the heart&#xD;
             (ventricular dysfunction or valve disease)&#xD;
&#xD;
          -  Tricuspid or mitral valve replacement or repair&#xD;
&#xD;
          -  If female of childbearing potential - pregnant or breastfeeding&#xD;
&#xD;
          -  Patient has a bleeding diathesis or suspected pro-coagulant state&#xD;
&#xD;
          -  Patient has contraindication to long-term antithromboembolic therapy (e. g.&#xD;
             acetylsalicylic acid, heparin, warfarin)&#xD;
&#xD;
          -  Presence of condition that precludes appropriate vascular access&#xD;
&#xD;
          -  Heart disease in which corrective surgery is anticipated within 6 months&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Patient has a known sensitivity to contrast media (if needed during the procedure)&#xD;
             that cannot adequately be controlled with pre-medication (or totally excluded)&#xD;
&#xD;
          -  Patient has other anatomic or co-morbid conditions that, in the Investigator's&#xD;
             opinion, could limit the patient's ability to participate in the study or to comply&#xD;
             with follow-up requirements, or impact the scientific soundness of the study results&#xD;
&#xD;
          -  Patient is currently participating in another clinical trial&#xD;
&#xD;
          -  Patient is unlikely to survive over one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios St Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

